Serina Therapeutics (SRNE) Highlights Parkinson's Research at Conference

Serina Therapeutics (SRNE) participated in the H.C. Wainwright conference, presenting advancements in its Parkinson's disease research. The company is focusing on developing innovative therapies aimed at improving patient outcomes. This event is significant as it highlights the company's commitment to addressing a critical health issue and may attract investor interest due to its potential market impact. An emphasis on breakthrough therapies could lead to positive momentum for the company's stock.